Statements (22)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:monoclonal_antibody
|
| gptkbp:administeredBy |
intravenous infusion
|
| gptkbp:affiliatedWith |
antineoplastic agent
|
| gptkbp:alternativeName |
SYD-985
SYD985 trastuzumab-SYD985 conjugate |
| gptkbp:CASNumber |
1807530-32-6
|
| gptkbp:clinicalTrialPhase |
Phase III
|
| gptkbp:developedBy |
Synthon Biopharmaceuticals
|
| gptkbp:hasComponent |
gptkb:trastuzumab
duocarmazine |
| gptkbp:hasOrphanDrugStatus |
yes
|
| https://www.w3.org/2000/01/rdf-schema#label |
Trastuzumab duocarmazine
|
| gptkbp:indication |
HER2-positive metastatic breast cancer
|
| gptkbp:mechanismOfAction |
delivers cytotoxic agent to HER2-positive cells
|
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:target |
HER2
|
| gptkbp:UNII |
1Q1K6P2J1N
|
| gptkbp:usedFor |
gptkb:cancer
solid tumors |
| gptkbp:bfsParent |
gptkb:Servier_Pharmaceuticals
|
| gptkbp:bfsLayer |
7
|